Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G J Hatheway

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Hospital Formulary|July 10, 1982
Areawide survey of antimicrobial restriction policies and the role of hospital pharmacistsG J Hatheway
Drug Intelligence & Clinical Pharmacy|November 1, 1982
Doxycycline-induced esophagitisG J Hatheway
American Journal of Hospital Pharmacy|July 1, 1990
Concentrated morphine sulfate injectionS P Edgar, G J Hatheway
Journal of Medicinal Chemistry|August 1, 1976
Centrally acting emetics. 10. Rigid dopamine congeners derived from octahydrobenzo[f]quinolineJ G Cannon, G J Hatheway
Journal of Medicinal Chemistry|June 1, 1978
Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 2. On the role of correlation analysis in decision making in drug modification. Toxicity quantitative structure-activity relationships of 1-(X-phenyl)-3,3-dialkyltriazenes in miceC Hansch, G J Hatheway, F R Quinn, et al.
Journal of Medicinal Chemistry|May 1, 1979
Ames test of 1-(X-phenyl)-3,3-dialkyltriazenes. A quantitative structure-activity studyB H Venger, C Hansch, G J Hatheway, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 1, 1976
Inhibition of the sympathetic nervous system by a series of heterocyclic congeners of dopamineF M Sharabi, J P Long, J G Cannon, et al.
Antimicrobial Agents and Chemotherapy|June 1, 1982
Pharmacokinetics of cefonicid, a new broad-spectrum cephalosporinS L Barriere, G J Hatheway, J G Gambertoglio, et al.
Journal of Medicinal Chemistry|June 1, 1978
Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 1. Quantitative structure-activity relationships vs. L1210 leukemia in miceG J Hatheway, C Hansch, K H Kim, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Hospital Formulary|July 10, 1982
Areawide survey of antimicrobial restriction policies and the role of hospital pharmacistsG J Hatheway
Drug Intelligence & Clinical Pharmacy|November 1, 1982
Doxycycline-induced esophagitisG J Hatheway
American Journal of Hospital Pharmacy|July 1, 1990
Concentrated morphine sulfate injectionS P Edgar, G J Hatheway
Journal of Medicinal Chemistry|August 1, 1976
Centrally acting emetics. 10. Rigid dopamine congeners derived from octahydrobenzo[f]quinolineJ G Cannon, G J Hatheway
Journal of Medicinal Chemistry|June 1, 1978
Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 2. On the role of correlation analysis in decision making in drug modification. Toxicity quantitative structure-activity relationships of 1-(X-phenyl)-3,3-dialkyltriazenes in miceC Hansch, G J Hatheway, F R Quinn, et al.
Journal of Medicinal Chemistry|May 1, 1979
Ames test of 1-(X-phenyl)-3,3-dialkyltriazenes. A quantitative structure-activity studyB H Venger, C Hansch, G J Hatheway, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 1, 1976
Inhibition of the sympathetic nervous system by a series of heterocyclic congeners of dopamineF M Sharabi, J P Long, J G Cannon, et al.
Antimicrobial Agents and Chemotherapy|June 1, 1982
Pharmacokinetics of cefonicid, a new broad-spectrum cephalosporinS L Barriere, G J Hatheway, J G Gambertoglio, et al.
Journal of Medicinal Chemistry|June 1, 1978
Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 1. Quantitative structure-activity relationships vs. L1210 leukemia in miceG J Hatheway, C Hansch, K H Kim, et al.
Pageof 1